论文信息 - Ushering in a New Era of Alzheimer Disease Therapy. - 字舞流文

Ushering in a New Era of Alzheimer Disease Therapy.

N. Chin | E. Widera | S. Brangman

[1] L. Apostolova,et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. , 2023, JAMA.

[2] B. Landon,et al. Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program. , 2023, JAMA internal medicine.

[3] G. Rabinovici,et al. Lecanemab: Appropriate Use Recommendations , 2023, The Journal of Prevention of Alzheimer's Disease.

[4] S. Ayton,et al. Accelerated Brain Volume Loss Caused by Anti–β-Amyloid Drugs , 2023, Neurology.

[5] M. Thambisetty,et al. Lecanemab trial in AD brings hope but requires greater clarity , 2023, Nature Reviews Neurology.

[6] R. Bateman,et al. Lecanemab in Early Alzheimer's Disease. , 2022, The New England journal of medicine.

[7] S. Brangman. Achieving diversity in study populations: The importance of community engagement , 2022, Journal of the American Geriatrics Society.

[8] S. Arnold,et al. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US. , 2022, JAMA neurology.

[9] A. Kesselheim,et al. Revisiting FDA Approval of Aducanumab. , 2021, The New England journal of medicine.

[10] E. Peterson,et al. Representation of Older Adults in Cardiovascular Disease Trials Since the Inclusion Across the Lifespan Policy. , 2020, JAMA internal medicine.

[11] M. Lauer,et al. Inclusion Across the Lifespan: NIH Policy for Clinical Research. , 2018, JAMA.